Gilead Sciences, Inc. (FRA:GIS)
Germany
· Delayed Price · Currency is EUR | Market Cap | 119.53B |
| Revenue (ttm) | 26.59B |
| Net Income (ttm) | 5.52B |
| Shares Out | n/a |
| EPS (ttm) | 4.38 |
| PE Ratio | 21.66 |
| Forward PE | 13.28 |
| Dividend | 2.87 (3.02%) |
| Ex-Dividend Date | Mar 14, 2025 |
| Volume | n/a |
| Average Volume | 803 |
| Open | 95.14 |
| Previous Close | 95.18 |
| Day's Range | 95.14 - 95.14 |
| 52-Week Range | 58.03 - 111.04 |
| Beta | n/a |
| RSI | 53.35 |
| Earnings Date | Aug 1, 2025 |
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.
Financial numbers in USD Financial StatementsNews
Gilead succeeds in late-stage trial for breast cancer therapy Trodelvy as a first line option
ASCENT-03: Trodelvy Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy (sacituzumab govitecan-hziy). The study met its primary endpoint, demonstrati...
ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy). The stud...
Final Trade: WMT, GILD, DECK, ROST
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Final Trade: WMT, GILD, DECK, ROST
The final trades of the day with CNBCs Melissa Lee and the Fast Money traders.
Gilead to buy certain Hookipa Pharma assets for up to $10M
Gilead Sciences, Inc. (GILD) RBC Capital Markets Global Healthcare Conference (Transcript)
Tomas Cihlar, Gilead Sciences, Named to TIME’s List of 100 Most Influential People in the World for HIV Research
NORTHAMPTON, MA / ACCESS Newswire / May 20, 2025 / Congratulations to our very own Tomas Cihlar, Senior Vice President of Research, Virology, for being named to TIME's list of the 100 Most Influential...
Is this Gilead? Nope, just Georgia.
A brain-dead woman is being forced to carry a baby to term, and we are in hell.
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present more than 20 abstracts across both Gilead and Kite at the upcoming 2025 American Society ...
Gilead Sciences: Bringing PBC Into Focus Through Art of Patient Stories
NORTHAMPTON, MA / ACCESS Newswire / May 15, 2025 / "Living with primary biliary cholangitis (PBC) can be an isolating experience," explains Dilek, a mother of two from Germany who suffers from the rar...
Gilead Sciences Is Overvalued Now (Rating Downgrade)
Gilead Sciences, Inc. (GILD) BofA Securities Health Care Conference Transcript
Gilead Sciences, Inc. (NASDAQ:GILD) BofA Securities Health Care Conference May 13, 2025 2:20 PM ETCompany ParticipantsJohanna Mercier – Chief Commercial...
The 2024 Responsible Business and Impact Report Shares How Gilead Sciences Is Driving Change
NORTHAMPTON, MA / ACCESS Newswire / May 13, 2025 / At Gilead, we innovate for impact. This commitment helps us drive scientific solutions forward, reach more people in more places and protect the plan...
US stocks close sharply higher on US China tariff news
The major US stock indices are sharply higher on US/China tariff news. Over the weekend the US slashed tariffs for the next 90-days on China goods from 145% to 30% inclusive of a 20% tariff due to fen...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Earth Day Focus for Gilead Sciences - Every Action Has an Impact
NORTHAMPTON, MA / ACCESS Newswire / May 8, 2025 / Creating a healthier world for all starts with taking care of the one we all share. As one of America's Greenest Companies, we're always working to en...
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Rep. Marjorie Taylor Greene (R-Ga.) has been actively buying stocks in 2025, including transactions that may have been perfectly timed during a market dip. Here's the latest transactions made by the c...
Gilead to invest about $32B in U.S. manufacturing through 2030
Gilead announces $11 billion in new investments in US
Gilead Sciences on Wednesday announced $11 billion in capital and operational investments in the U.S. to supplement an already planned spending of $21 billion in domestic manufacturing and R&D through...
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of ...
Gilead's Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025 | GILD Stock News
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
– 90% of Adults with Chronic Hepatitis Delta Virus (HDV) who Achieved Undetectable HDV RNA at 96 Weeks of Treatment with Bulevirtide Remained Undetectable for Almost 2 Years After Stopping Treatment –...
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced final results from the pivotal Phase 3 MYR301 study revealing that 36% (23 out of 64) of adults living with ch...